Conference Coverage

Investigational Contraceptive Patch Shows Promise


 

FROM THE ANNUAL MEETING OF THE AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS

The investigators reported one serious adverse event in the oral contraceptive group (one case with an unspecified liver problem) and three adverse events in the AG200-15 group (one case with a blood clot in the left subclavian vein, one case of uncontrollable nausea and vomiting, and one case of drug overdose with Benadryl) to be possibly or probably related to the study drug.

Going forward, Dr. Kaunitz said that he would like to see clinical trials of AG200-15 that involve shorter hormone intervals than the classic schedule of 21 active tablets followed by 7 hormone-free days as followed in this study. "Newer contraceptives tend to have shorter hormone-free intervals or be continuous," he said. "Going forward, I’d be interested in clinical trials of this patch using hormone-free intervals shorter than 7 days or cycles longer than 1 month."

Agile Therapeutics has submitted a New Drug Application for AG200-15 with the Food and Drug Administration.

The study was funded by Agile Therapeutics. Dr. Kaunitz disclosed that he is a consultant for the company.

Pages

Recommended Reading

Newer Progestogens: Study Confirms VTE Risk
MDedge ObGyn
FDA Panel: Ortho Evra Benefits Outweigh Risks
MDedge ObGyn
FDA Panel Reviews VTE Risk for Some OCs
MDedge ObGyn
FDA: OCs Containing Drospirenone May Increase Blood Clot Risk
MDedge ObGyn
Hormonal Contraceptives Insignificantly Lower Vitamin B12 Levels
MDedge ObGyn
Remove the black-box warning for depot medroxyprogesterone acetate!
MDedge ObGyn
Not all contraceptives are suitable immediately postpartum
MDedge ObGyn
How to prepare your patient for the many nuances of postpartum sexuality
MDedge ObGyn
How to choose a contraceptive for your postpartum patient
MDedge ObGyn
Drospirenone-containing birth control pills may increase risk of blood clots
MDedge ObGyn